Introduction
Myc is a typical oncoprotein that is involved in controlling a variety of cell behaviors, including cell cycle progression, proliferation, differentiation, survival, adhesion and control of cell size. 1, 2 In hematopoietic cells, Myc expression can be induced by hematopoietic cytokines and is responsible for mitogen-induced proliferation. Studies have suggested that Myc is a common downstream target for most leukemogenic oncogenes. 3 Deregulation of Myc, which induces high levels of proliferation and blocks the full differentiation of hematopoietic progenitor cells, might be an important event in the pathogenesis of most human hematopoietic malignancies, including MPDs, acute myeloid leukemia (AML), acute lymphocytic leukemia (ALL) and lymphoma. [3] [4] [5] [6] Pharmacological or genetic inhibition of Myc can repress the proliferation and induce the differentiation of leukemic blasts as shown by in vitro studies. Thus, Myc has been recognized as a potential molecular target for anti-leukemia drug development. 7 Myc transgenic mice develop different types of leukemias depending on the promoter used to drive Myc expression. Transgenic overexpression of Myc in B and T cells leads to the development of B-and T-cell leukemias and lymphomas, respectively, in mice. 8, 9 Overexpression of Myc in hematopoietic stem cells and progenitors (HSC/Ps) resulted in a significantly increased production of hematopoietic progenitor cells and excessive mature myeloid cells, a phenotype characteristic of MPDs, which was followed by AML or by T-or B-ALL development. 10 Transgenic overexpression of Myc in megakaryocytic/erythroid progenitors, which are progenitors for both megakaryocytes (Mks) and erythrocytes, leads to the development of erythroid leukemia. 11 Despite these extensive studies of the Myc protein, due to the co-expression of N-Myc and other potentially functionally redundant members of the Myc protein family in hematopoietic progenitor cells, 12 it remains unclear as to whether elimination of Myc is sufficient to completely inhibit the development of chronic and acute leukemias.
The phosphoinositide 3-kinase (PI3K)/Akt signaling pathway mediates proliferation, survival and migration signaling in hematopoietic cells stimulated by hematopoietic cytokines. As with Myc deregulation, constitutive activation of PI3K/Akt signaling promotes the uncontrolled growth of hematopoietic cells, which is commonly detected in MPDs, AML, ALL and lymphomas, accounting for practically all types of human hematopoietic tumors. 13 Mice with transgenic overexpression of a constitutively active form of Akt initially develop MPDs, which are followed by AML and/or T-cell lymphoma. 14 Because of their significant impact on the pathogenesis of hematopoietic malignancies, molecules that are involved in mediating PI3K/ Akt signaling have also been identified as therapeutic targets in the development of anti-leukemic drugs. 15 It was known that PI3K/Akt signaling stabilizes the Myc protein by inducing glycogen synthase kinase 3b-mediated phosphorylation or by inhibiting protein phosphatase 2A-mediated dephosphorylation. 16, 17 Levels of Pten protein (phosphatase and tensin homolog, deleted on chromosome ten), a negative regulator of PI3K/Akt signaling, are negatively correlated with Myc levels in many acute T-lymphocytic leukemia (T-ALL) patient samples. 17 However, it is still unknown as to whether the proliferation and survival of leukemic blasts induced by activated PI3K/Akt signaling is dependent upon Myc activity.
It was found that Pten inactivation is one of the major causes of the constitutive activation of PI3K/Akt signaling in leukemia. [18] [19] [20] [21] [22] In addition to mutations that were commonly found in T-cell leukemia/lymphoma, 20, 23, 24 the expression and activity of Pten are downregulated in most myeloid and lymphocytic leukemia samples by multiple different mechanisms, such as epigenetic repression 25 or post-translational inhibition. It was reported that the phosphatase activity of Pten is negatively regulated by phosphorylation of its C-terminal tail. 26 Interestingly, the phosphorylated form of Pten was detected in leukemic blasts from most leukemic samples, including AML, chronic lymphocytic leukemia and the Pten-expressing T-ALL. Thus, Pten phosphorylation correlates well to the increased PI3K/Akt activity in the same leukemia samples. 19, 20, 22 Pten is expressed in most hematopoietic cells, including HSC/ Ps. Mice with Pten deletion in HSC/Ps develop MPDs, as shown by significantly enhanced granulocyte expansion and tissue infiltration, which progress to AML or T-ALL after cells sustain additional mutations. [27] [28] [29] T-cell-specific Pten À/À mice develop lymphoproliferative disorders (LPDs) and then a fatal CD4 þ / CD8
À lymphoma after a 3-to 4-month latency period. Additional mutations are required for these lymphoproliferative pre-malignant conditions to progress to full malignancy. 30 The Myc gene has been found to be affected by such additional mutations. 29 The progression of these diseases observed in Pten À/À mice is reminiscent of the progression of human MPD to leukemia and of LPD transformation to lymphoma.
We found that all four types of hematopoietic disorders, MPDs, LPDs, leukemia and lymphoma, developed in our interferon (IFN)-inducible Pten À/À mice depending on how the mice were maintained. To investigate whether Myc is required for the activated PI3K/Akt-induced proliferation and survival of hematopoietic cells, and to study whether Myc is required for the development of MPDs and polyclonal LPDs, as well as whether Myc is essential for leukemia/lymphoma transformation in Pten À/À mice, we generated IFN-inducible Pten/Myc doubleknockout mice (Pten À/À /Myc À/À ) to assess whether the deletion of Myc is able to prevent the development of these premalignancies and malignancies in Pten À/À mice. We found that, as is the case with Pten À/À mice, Pten À/À /Myc À/À mice develop MPDs and LPDs. However, none of our Pten À/À /Myc À/À mice developed acute leukemia or lymphoma. 
Materials and methods

Generation of inducible
Hematopoietic phenotype analysis
After mice were killed at the indicated times, peripheral blood (PB), bone marrow (BM), spleens, thymus glands and lymph nodes were collected. Cellular components of the PB of mutant mice were examined by CBC. The percentages and absolute numbers of different lineages of hematopoietic cells in BM, spleens, thymuses and lymph nodes were also examined by different combinations of cell-surface marker staining as indicated in the text and by flow cytometric analysis as described. 27 
q-PCR and qRT-PCR
DNA was extracted by phenol/chloroform extraction. RNA was isolated using RNeasy Plus Mini kit (Qiagen, Valencia, CA, USA). cDNA was prepared using SuperScript First-Strand Synthesis System (Invitrogen, Carlsbad, CA, USA). Quantitative PCR (q-PCR) for detecting Myc and Pten DNA copies as well as Myc and Pten mRNA expression levels were conducted by using SYBR Green PCR Master (Applied Biosystems, Carlsbad, CA, USA). Information concerning the primers used can be found in Supplementary Table 1 . Triplicate reverse transcription (RT)-PCRs were also performed.
Acetylcholinesterase staining
Fresh-frozen spleen sections were fixed in ice-cold acetone for 5 min. After drying at room temperature, tissue sections and colony slides were stained with freshly prepared acetylcholinesterase staining solution containing 0.5 mg/ml acetylthiocholiniodide, 5 mM sodium citrate, 3 mM copper sulfate and 0.5 mM potassium ferricyanide in 0.1 M sodium phosphate buffer. After a 3-h incubation at room temperature, the staining solution was poured off and sections were fixed in 95% ethanol for 10 min. Slides were then counterstained with Harris' hematoxylin solution for 30 s.
Histological analysis
Wild-type (WT) and mutant mice were killed, and spleens, livers and kidneys were collected immediately. After 2-3 days fixation in zinc formalin, spleen and liver tissues were embedded in paraffin. Sections were cut for hematoxylin and eosin staining or antibody immunostaining.
BrdU incorporation
Four hours before being killed, mice were injected with bromodeoxyuridine (BrdU) at 50 mg/g body weight. The percentages of BrdU þ cells among CD4 þ lymphocytes in lymph nodes, Gr1 þ granulocytes in BM and CD41 þ Mks in spleens were assessed by cell-surface marker staining followed by cell permeabilization and BrdU antibody staining, as reported previously. BrdU in situ histological staining was conducted as reported previously. 35 
Activation-induced cell death of T-lymphocytes
CD3
þ T-lymphocytes were purified from spleens of WT, Pten À/À /Myc À/ þ and Pten À/À /Myc À/À mice 30 days after polyI:C injections. A total of 2 Â 10 6 cells were cultured at 37 1C in 24-well plates in 2 ml RPMI 1640 medium containing 10% fetal bovine serum, soluble anti-CD3e (clone 145-2C11; 3 mg/ml) and murine rIL-2 (R&D, Minneapolis, MN, USA; 25 U/ml) for 48 h to induce activation. Three hours before being harvested, half of the cells were treated with BrdU (10 mM final concentration) for pulse labeling. Activation-induced proliferation was examined by allophycocyanin-conjugated BrdU antibody staining and flow cytometric analysis. Activation-induced Fas expression was detected by allophycocyanin-conjugated CD95 antibody staining and flow cytometric analysis. The remaining half of the activated T cells was harvested, washed and 0.5 Â 10 6 /ml of them were re-plated into 96-well plates with rIL-2, followed by 10 ng/ml tumor necrosis factor-a (e-Bioscience, San Diego, CA, USA; Cat. No. 14-8321) or 20 ng/ml of FasL (BD Bioscience, Franklin Lakes, NJ, USA; clone Jo2, Cat. No. 554254), together with 2 mg/ml of protein G for the stimulation of apoptosis. Twenty four hours post-stimulation, 50 mM propidium iodide (PI) was added to the cells for 15 min at room temperature. Cell viability was determined by flow cytometric analysis of the percentage of PI À cells.
Fas-induced granulocyte death
Gr1 þ granulocytes were isolated from BM of WT, Pten À/À / Myc À/ þ and Pten À/À /Myc À/À mice 30 days after polyI:C injections and incubated in RPMI 1640 medium containing 10% fetal bovine serum and 20 ng/ml of granulocyte/macrophage-colony-stimulating factor with or without 20 ng/ml of FasL. After 12 h of incubation, cells were stained with PI, followed by flow cytometric analysis for cell viability.
Cell migration assay
CD4
þ T-lymphocytes were isolated from spleens and Gr1 þ granulocytes were isolated from BM of WT, Pten À/À /Myc
and Pten À/À /Myc À/À mice 30 days after polyI:C injections. The migration of these cells was examined in 96-transwell plates by assessing their response to 300 ng/ml of stromal cell-derived factor-1 3 h after initiation of incubation. 27 
Statistical analyses
T-tests were performed to assess the statistical significance of observed changes. 27 By further analysis, we found that these inducible Pten À/À mice also develop the same lymphadenopathy as early as 20 days after the induction of Pten mutation, as demonstrated by enlarged lymph nodes due to lymphocytic hyperplasia (Figure 1a ). Lymphadenopathy affects mainly the submandibular and axillary lymph nodes. At the time of death, most lymph nodes were between 0.4 and 1 cm in size, the average size being 0.6 ± 0.35 cm in diameter. The significant increase in both B-lymphocytes (B220 þ ) and T-lymphocytes (CD4 þ or CD8 þ ) in the enlarged lymph nodes suggests that it is a polyclonal lymphoproliferative feature (Figure 1b) . Pten deletion in these B-and T-lymphocytes was confirmed by q-PCR to detect Pten copy number and mRNA expression levels (Figures 1c and d ).
Results
Early
Spontaneous Pten deletion in a small percentage of hematopoietic cells of Mx1Cre þ Pten fx/fx mice due to the leakage of Cre expression is sufficient to induce T-cell lymphoma development
The Mx1Cre mice we used in our studies are an IFN-inducible Cre line. 33 Owing to the existence of basal background levels of IFN in mice during conditions of normal homeostasis, low levels of leakage were expected when using this mouse line to generate conditional-knockout mice. To examine the To study whether this low percentage leakage of Mx1Cre is sufficient to induce hematopoietic malignancy in Mx1Cre þ CD8 À T-cell lymphoma within 3-4 months, exactly the same type of lymphoma reported in T-cell-specific Pten À/À mice ( Figure 2b ). All these mice showed significantly enlarged thymuses and lymph nodes (Figure 2c ), as well as splenomegaly and hepatomegaly (data not shown). As many as 80-95% of CD4 þ lymphomic blasts could be detected in thymus, spleen, lymph nodes, PB and BM immediately before the mouse was euthanized (Figure 2d ). Post-mortem analyses revealed that lymphomic blasts had infiltrated multiple tissues (Figures 2e-g (Figures 3a and b) . These data suggested that deregulation of Myc in the leukemic and lymphomic blasts of Pten À/À mice might be a consequence of additional mutations, which may be critical for the development of acute, but not chronic hematopoietic malignancies.
Myc is essential for the pathogenesis of T-cell lymphoma, but not for the lymphadenopathy of Pten-mutant mice (Figure 4a) , as demonstrated by enlarged lymph nodes (Figure 4d ), due to the expansion of both T (CD4 þ or CD8 þ ) and B (B220 þ ) lymphocytes (Figure 4e ). Lymph nodes were between 1 and 2 cm in size and averaged 1.6±0.65 cm in diameter when examined at 8 months of age (Figure 4d ). However, in spite of the high activity of PI3K/Akt signaling in the mutant lymphocytes (Figure 4g) 
Myc deletion converts Pten
À/À MPDs from granulocytedominated conditions to megakaryocyte-dominated conditions
We and others reported that Mx1Cre þ Pten fx/fx mice die between 25-40 days after polyI:C injection with a typical MPD syndrome, as demonstrated by significantly increased white blood cell counts in PB due to increased granulocytes, as well as splenomegaly/hepatomegaly due to granulocyte infiltration. [27] [28] [29] We also reported that Myc is required for the proliferation of most lineage-committed hematopoietic progenitors, but not megakaryocytic progenitors. Myc-knockout mice (Myc À/À ) developed a symptom triad of anemia-leukopeniathrombocytosis due to a significant reduction in the production of granulocytes and erythrocytes and a correspondingly significant increase in megakaryopoiesis. 37 To study whether Myc is essential for the development of MPDs in Pten À/À mice, we induced deletions of the Pten and Myc genes in a cohort of 18 þ and CD4 þ cells isolated from WT, Pten À/À MPD/lymphadenopathy mice, as well as leukemic/ lymphomic blasts from Pten À/À mice using qRT-PCR (a) and western blot assays (b). Relative Myc mRNA levels for each sample were normalized to the mRNA levels of its GAPDH gene. Data are a summary of triplicate experiments (a, c). Pten deletion in Pten À/À cells was confirmed by q-PCR to detect the levels of Pten genomic DNA. Pten DNA levels for each sample were normalized to GAPDH DNA levels first and then normalized to Pten DNA levels of WT Gr1 þ granulocytes (Sample 1). Samples shown in the figure were as follows: (Figure 5a and Supplementary data 2-3). However, white blood cell counts were comparable to those of WT controls despite the greater range in the counts, as indicated by high standard deviations (Figure 5a ).
In careful post-mortem dissections of the mice, we found significant splenomegaly and hepatomegaly in Pten À/À /Myc (Figures 5k-m) . Colonized growth and abnormally high proliferation of Mks in these mice were confirmed by BrdU pulse labeling (Figures 5k-m) . Small Mks could be observed occasionally in the PB of the double-mutant mice (Supplementary data 3E) . Furthermore, we found significant fibrosis in the spleens of some Pten 
Myc is required for the transformation of MPD to acute leukemia
We know that recipient mice which received Pten À/À BM cells developed exactly the same MPDs as the original Pten À/À mice, and that these conditions progress to T-ALL or AML when the animals' cells sustain additional mutations within 3-4 months after transplantation. [27] [28] [29] However, we found that the MPDs from Pten À/À /Myc À/À mice were non-transplantable, although increased levels of PI3K/Akt signaling activity were detected in BM cells from Pten 
Role of Myc in acute leukemic transformation J Zhang et al
Lethally-irradiated recipient mice, which received 5 Â 10 6 Pten À/À /Myc À/À BM MNCs, survived for only 1-1.5 months owing to failure of hematopoietic reconstitution. The doublegene mutant HSC/Ps generated node-like growths in the spleens of recipient mice, with Mks predominating in these nodes (Figures  6a-d) . Mks located within these nodes were found to be undergoing apoptosis (Figure 6d ). To study whether Myc is required for the transformation of Pten À/À MPDs to acute leukemia, we transplanted BM MNCs from Pten À/À /Myc À/À mice (CD45.2 þ ) into lethally-irradiated recipient mice (CD45.1 þ ), with the support of BM cells from WT mice (CD45.1 þ ). This was carried out to determine whether or not Myc deletion is able to block leukemic transformation. BM MNCs from Pten
were transplanted in parallel as positive controls. We found that all mice receiving Pten (Figures 6e-i) . However, all eight recipients that received Pten À/À /Myc À/À BM survived for 1 year without any signs of leukemia (Figure 6e) , although approximately 1-3% of CD45.
donor origin) could still be detected in the BM of recipient mice at the time of the completion of the experiment (data not shown). These data suggested that Myc is required for the development of acute leukemia in Pten À/À mice.
Myc is necessary for the proliferation of the Pten À/À granulocytes and lymphocytes, but is not essential for their invasiveness nor their resistance to apoptosis
It has been proposed that the high degree of proliferation, increased migration and low apoptotic index of Pten À/À cells might be critical for the development of both pre-leukemic proliferative disorders and leukemia in Pten À/À mice. We wanted to study which of these behavior changes in Pten À/À cells are independent of Myc and are contributory to preleukemic proliferative disorders and which changes are Mycdependent and are essential for leukemic/lymphomic transformation. To do this, we compared the proliferation, apoptosis and migration of Gr1 þ cells isolated from the BM of Pten
À/À MPD and WT control mice, as well as CD4 þ cells from lymph nodes of
À/À /Myc À/À lymphadenopathy and WT control mice. We found that the proliferation of Gr1 þ and CD4 þ cells from Pten À/À /Myc þ /À MPDs/LPDs is comparable to that of their counterparts in WT controls, but is significantly increased in the blasts of Pten À/À /Myc þ /À AML and lymphomic mice. Homozygous deletion of Myc significantly inhibits the proliferation of both populations of cells, as shown in Pten À/À /Myc À/À MPD and LPD mice (Figures 7a and b) . Interestingly, compared to WT controls, Gr1 þ and CD4 þ cells from Pten À/À mice are resistant to Fas-induced apoptosis (Figures 7f and g ) owing to decreased Fas expression (Figure 7e) , and are more sensitive to stromal cell-derived factor-1-induced migration (Figure 7h ) independent of the status of the Myc gene. In addition, consistent with our previous reports that the proliferation of Mks is less dependent on Myc, we found that the proliferation of CD41 þ Mks is promoted by Pten deletion even in a Myc À/À background (Figure7c and Supplementary data 7) . However, the increased apoptosis and low ploidy of Myc À/À Mks is not reversed by Pten deletion (Supplementary data 5) .
Discussion
Inactivation of Pten and/or constitutive activation of PI3K/Akt are commonly found in both human chronic and acute 
G. [27] [28] [29] [38] [39] [40] It was found that PI3K/Akt signaling prevents the degradation of Myc protein, suggesting that Myc might be required for PI3K/ Akt signaling-induced cell proliferation and leukemia development. 16, 17 Interestingly, we found that activation of PI3K/Akt signaling by Pten gene deletion was unable to elevate the levels of Myc protein in hematopoietic cells. In fact, Myc expression is only significantly elevated after acute malignant transformation of Pten À/À cells. Consistent with this observation, our genetic studies demonstrated that Myc protein is absolutely required for acute malignant progression but is not essential for the chronic hyperplasia seen in Pten À/À mice. Consistent with the results of our previous studies, we found that Myc deletion converts Pten À/À MPDs from granulocyte-dominated conditions to Mkdominated conditions due to the selective requirement for Myc in the proliferation of most lineages of hematopoietic progenitors, but not for the proliferation of Mk progenitors. 37 In addition, despite the fact that N-Myc is expressed in hematopoietic cells, its levels are not increased in Pten À/À cells at either the chronic proliferative lesion or acute leukemia/lymphoma stages (data not shown). The fact that Pten À/À /Myc À/À mice failed to develop leukemia/lymphoma indicated that endogenous N-Myc cannot replace c-Myc activity during leukemia development in Pten À/À mice. Our studies suggest that PI3K/Akt signaling mainly stimulates a survival signal in hematopoietic cells. The apoptotic resistance of Pten-mutant cells is the major cause of chronic proliferative disorders. Our studies support the notion that Myc is the common target of additional mutations that lead to the progression of chronic proliferative disorders toward the development of acute leukemia/lymphoma. þ and Gr1 þ cells was analyzed 3 h after stromal cell-derived factor-1 induction. *Significant difference compared to WT controls.
Role of Myc in acute leukemic transformation J Zhang et al
The unbiased leakage of Mx1Cre in hematopoietic cells provides a useful tool for leukemia and lymphoma research
The Mx1Cre mouse is an IFN-inducible Cre line. Because it is nearly 100% efficient in inducing loxp site-mediated recombination in hematopoietic cells, including HSCs, upon polyI:C injection, the Mx1Cre mouse has been routinely used to study gene functions in adult hematopoiesis. [27] [28] [29] 35 However, in normal housing conditions, low levels of leakage are expected even in non-polyI:C-injected animals due to basal levels of IFN expression. Approximately 2-3% leakage was detected in this Cre line in all lineages of hematopoietic cells without cell-type bias. By crossing this Cre line with different loxp mouse lines, spontaneous gene recombination event(s) induced by Mx1Cre can be used to turn on or turn off expression of specific gene(s) in a small percentage of hematopoietic cells without any particular cell lineage bias. In fact, this scenario might better reflect the spontaneous nature of actual gene mutations in human hematopoietic cells. Only the mutations that induce the dominant growth of certain populations of hematopoietic cells due to the activation of certain oncogenes or inactivation of certain tumor suppressors will result in hyperplasia or leukemia/ lymphoma. By using this Cre line, we generated a Pten-mutant animal model, which develops T-cell lymphoma under normal housing conditions owing to the dominant growth of mutant CD4 þ lymphocytes.
Myc is not essential for the development of lymphadenopathy nor MPDs, but is absolutely required for the transformation to acute leukemia and lymphoma in Pten À/À mice b-Catenin is a critical mediator of Wnt signaling, the activity of which is higher in HSCs and might play important roles in HSC self-renewal. [41] [42] [43] Abnormal activation of b-catenin has been detected in leukemic stem cells in human and murine CML at crisis phase (CML-BC), 43, 44 as well as in murine Pten À/À T-ALL and AML. 29 Heterozygous b-catenin mutation did not block MPD development in Pten À/À mice, but significantly inhibited T-ALL/ AML transformation in these same mice. These studies suggested that b-catenin might be critical for the transformation of MPD to leukemia and plays critical roles in the self-renewal of leukemic stem cells in CML-BC. 29, 43 Interestingly, Zhao et al. 42, 44 demonstrated that b-catenin is required for the self-renewal of leukemic stem cells of Bcr/Abl-induced CML, but is not essential for the selfrenewal of leukemic stem cells of Bcr/Abl-induced acute B lymphocytic leukemia (B-ALL). Homozygous deletion of b-catenin in murine HSC/Ps is able to repress Bcr/Abl fusion protein-induced CML development, but cannot prevent fusion protein-induced B-ALL development. 42 The authors proposed that CML stem cells might originate from normal HSCs, which require b-catenin for their long-term self-renewal, whereas B-ALL stem cells might originate from pro-B cells, which are independent of b-catenin for their self-renewal. The molecular mechanism for this differential requirement for b-catenin in MPD-leukemia syndromes in Pten À/À mice and CML-B ALL syndromes in Bcr/Abl transgenic mice merits further investigation.
Myc has been identified as a direct target of Wnt-b-catenin signaling. Inactivation of Myc prevents tumorigenesis induced by abnormal Wnt-b-catenin activation in adenomatous polyposis colimutant mice. In hematopoietic cells, Myc expression increases rapidly in response to growth factor stimulation, 45, 46 which is required for the proliferation of the majority hematopoietic cells, but not HSCs nor Mks. 37 Mice with Myc-deleted HSCs develop a thrombocytosis-anemia-leukopenia triad of symptoms due to a significant increase in megakaryocytosis and a concomitant reduction in erythropoiesis and myelopoiesis. 37 Studies of T-cellspecific knockout mice suggested that Myc is required for cell growth and proliferation in immature thymocytes at the pre-TCR checkpoint, 47, 48 in stage 0 progenitors of invariant Va14-bearing natural killer T cells, 49, 50 and in memory CD8 þ T cells. 51 However, the differentiation and survival of these thymocytes seems not to be impaired in Myc-deficient mice. T lymphocytes with Myc deletion fail to expand in response to T-cell receptor signaling, although most active markers are expressed. 47 The development of lymphadenopathy in Pten À/À /Myc À/À mice suggested that the polyclonal lymphocytic hyperplasia seen in Pten-mutant animals was not due to increased Mycdependent proliferation and subsequent increased lymphocyte generation but was a consequence of resistance to apoptosis in these mutant peripheral lymphocytes (peripheral tolerance). We found that thymocyte development in the thymus glands of Pten À/À /Myc À/À mice was exactly the same as was seen in Myc single gene-knockout mice (Supplementary data 8) . 37, 47 The conversion of Pten À/À MPDs from granulocyte-dominated to Mk-dominated syndromes by Myc deletion supports our previous finding that Mks are less dependent on Myc for their proliferation than are granulocytes. 37 The fact that ALL/AML or lymphoma do not develop in Pten À/À /Myc À/À mice indicates the essential role of Myc in the transformation of these lymphomyeloid hyperplasias to acute malignancies. However, it remains to be determined whether or not Myc is still required for the progression of such acute malignancies after they have developed. In addition, the fact that Pten À/À /Myc À/À MPDs resemble essential thrombocytosis suggests that Mks are significantly expanded. However, none of the recipients receiving Pten À/À /Myc À/À BM developed acute megakaryocytic leukemia due to increased apoptosis of the double-mutant Mks. We are actively investing whether protecting double-gene mutant Mks from apoptosis by introducing pro-survival signals is able to induce acute megakaryocytic leukemia.
Furthermore, germline mutations of the Pten gene cause a group of inherited autosomal dominant disorders called Pten hamartoma-tumor syndrome, including Cowden syndrome, Lhermitte-Duclos disease and Bannayan-Zonana syndrome, all characterized by developmental defects and benign growths in multiple organs (hyperplastic lesions such as hamartomatous polyps of the gastrointestinal tract, mucocutaneous lesions and trichilemmomas). These hyperplastic lesions show significantly increased risk for malignant transformation. 52, 53 Studies using tissue-specific Pten À/À suggested that inactivation of Pten alone results in benign tumor growth of multiple tissue cells, such as intestinal polyps and prostatic intraepithelial neoplasias. 54, 55 Additional mutations that result in gain-of-function of oncogenes and/or loss-of-function of other tumor suppressor genes might be absolutely required for the full development of malignancies. [27] [28] [29] [30] 32, 54, 55 It will be interesting to ascertain whether Myc is also required for the malignant transformation of these Pten-mutant benign tumors. 
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